Administration of branched-chain amino acids alters the balance between pro-inflammatory and anti-inflammatory cytokines. Issue 48 (February 2016)

• Record Type: Journal Article
• Authors: Rosa, Luciana; Scaini, Giselli; Furlanetto, Camila B.; Galant, Leticia S.; Vuolo, Francieli; Dall'Igna, Dhébora M.; Schuck, Patrícia F.; Ferreira, Gustavo C.; Dal-Pizzol, Felipe; Streck, Emilio L.
• Is Part Of: International journal of developmental neuroscience. Issue 48(2016:Feb.)
• Page Start: 24
• Page End: 30
• Publication Date: 2016-02
• Subjects: Branched chain amino acids -- Maple syrup urine disease -- Brain -- Cytokines; Developmental neurobiology -- Periodicals; Neurology -- Periodicals; Neurologie du développement -- Périodiques; Developmental neurobiology; Periodicals; 612.8
• DOI: 10.1016/j.ijdevneu.2015.11.002
• Languages: English
• ISSNs: 0736-5748

Abstract

Highlights: Acute H-BCAA increased IL-1β, IL-6, TNF-α levels in cerebral cortex of infant rats. Acute H-BCAA increased IL-6 and decreased IL-10 levels in hippocampus of infant rats. Acute H-BCAA no significant effect on cytokine levels in 30-day-old rats. Chronic administration of H-BCAA decreased IL-1β and IL-6 levels in cerebral cortex. Chronic administration of H-BCAA decreased IL-6, IL-10 and IFN-γ levels in hippocampus. Abstract: Acute leucine intoxication and neurologic deterioration can develop rapidly at any age as a result of net protein degradation precipitated by infection or psychological stress in patients with maple syrup urine disease (MSUD). Here, we investigated the effects of acute and chronic Hyper-BCAA (H-BCAA) administration on pro- and anti-inflammatory cytokines in the brains of rats. For acute administration, Wistar rats (10 and 30 days) received three injections of BCAA pool (15.8 μL/g at 1-h intervals) or saline, subcutaneously. For chronic administration, Wistar rats (7 days) received of BCAA pool or saline twice a day for 21 days, subcutaneously. Our results showed that acute administration of H-BCAA increased IL-1β (∼78%; p ≤ 0.009) and TNF-α (∼155%; p ≤ 0.026) levels in the cerebral cortex but not in the hippocampus of infant rats. Moreover, IL-6 levels were increased in the hippocampus (∼135%; p ≤ 0.009) and cerebral cortex (∼417%; p ≤ 0.008), whereas IL-10 levels were decreased only in the hippocampus (∼42%; p ≤ 0.009). However, repeated administration of H-BCAA decreased IL-1β (∼59%; p ≤ 0.047), IL-6 (∼70%; p ≤ 0.009) and IFN-γ (∼70%; p ≤ 0.008) levels in the cerebral cortex, whereas the IL-6 (∼67%; p ≤ 0.009), IL-10 (∼58%; p ≤ 0.01) and IFN-γ (∼67%; p ≤ 0.009) levels were decreased in the hippocampus. These findings suggest that a better understanding of the inflammatory response in MSUD patients may be useful to develop therapeutic strategies to modulate the hyperinflammatory/hypoinflammatory axis.